QuidelOrtho Corp
QuidelOrtho Corporation (Nasdaq: QDEL) develops, manufactures and sells diagnostic testing solutions spanning immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its products include laboratory analyzers and tests, rapid point-of-care tests, molecular platforms, and instruments and reagents… From the company’s description.
Over the twelve months to Sep 27, 2026, QuidelOrtho Corp reported revenue of $2.59B, down 4.5% from a year earlier, and a net loss of $369.20M. Its operating margin was −4.9%, and operations generated $7.90M in cash. In fiscal 2025, it reported revenue of $2.73B, down 1.9% from fiscal 2024, and a net loss of $1.13B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What QuidelOrtho Corp does
In the company’s own words
QuidelOrtho Corporation (Nasdaq: QDEL) develops, manufactures and sells diagnostic testing solutions spanning immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its products include laboratory analyzers and tests, rapid point-of-care tests, molecular platforms, and instruments and reagents for blood typing, compatibility testing and infectious-disease screening. Customers include hospitals, clinical and reference laboratories, physician offices, urgent care and retail clinics, pharmacies, blood banks, donor centers and consumers using over-the-counter tests. The company sells through its own sales force and distributors, and often places instruments under long-term contracts that support recurring sales of assays, reagents and consumables. It manages operations through five geographic reportable segments: North America, EMEA, China, JPAC and Latin America; products are organized into Labs, Molecular Diagnostics, Point of Care and Transfusion Medicine business units. Its brands include VITROS, ORTHO VISION, SOFIA, TRIAGE, QUICKVUE, LYRA and SOLANA. At year-end 2025, QuidelOrtho served customers in more than 140 countries and territories and had approximately 1,200 global service employees.
Company details
- Sector
- Health Care
- Industry (SIC)
- Chemicals
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- January
- CIK
- 1906324
- SIC
- 2835
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns QuidelOrtho Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · QuidelOrtho Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do QuidelOrtho Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of QuidelOrtho Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in QuidelOrtho Corp's last four quarterly filings that the numbers alone won't show?”